The Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Qutavina (teriparatide), from EuroGenerics Holdings, intended for the treatment of osteoporosis. Qutavina will be available as a solution for injection (20 micrograms/80 microlitres). Qutavina is a biosimilar medicinal product. It is highly similar to the reference product Forsteo (teriparatide), which was authorised in the EU on 10 June 2003. Data show that Qutavina has comparable quality, safety and efficacy to Forsteo.
Copyright © ICR (UK) Limited t/a International Medical Information (IMI). Registered in the UK Company no. 05894351
Disclaimer: All information on this site has been collated by healthcare professionals from around the globe. Where every possible step has been taken to ensure its accuracy, MedicalUpdateOnline cannot accept responsibility for the authenticity of the content matter.
Copyright: The copyright of the material on this site rests with the author unless otherwise indicated. It is a breach of copyright to use any material from this site without prior written consent.